PT2632479T - Péptidos de fviii para indução de tolerância imunitária e imunodiagnóstico - Google Patents

Péptidos de fviii para indução de tolerância imunitária e imunodiagnóstico

Info

Publication number
PT2632479T
PT2632479T PT117968461T PT11796846T PT2632479T PT 2632479 T PT2632479 T PT 2632479T PT 117968461 T PT117968461 T PT 117968461T PT 11796846 T PT11796846 T PT 11796846T PT 2632479 T PT2632479 T PT 2632479T
Authority
PT
Portugal
Prior art keywords
immunodiagnostics
immune tolerance
tolerance induction
fviii peptides
fviii
Prior art date
Application number
PT117968461T
Other languages
English (en)
Inventor
Nora Steinitz Katharina
Maria Wilhelmina Van Helden Paula
Maria Reipert Birgit
Schwarz Hans-Peter
Ehrlich Hartmut
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of PT2632479T publication Critical patent/PT2632479T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
PT117968461T 2010-10-27 2011-10-27 Péptidos de fviii para indução de tolerância imunitária e imunodiagnóstico PT2632479T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40740210P 2010-10-27 2010-10-27
US201161467894P 2011-03-25 2011-03-25
US201161502476P 2011-06-29 2011-06-29

Publications (1)

Publication Number Publication Date
PT2632479T true PT2632479T (pt) 2017-07-24

Family

ID=45349271

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117968461T PT2632479T (pt) 2010-10-27 2011-10-27 Péptidos de fviii para indução de tolerância imunitária e imunodiagnóstico

Country Status (20)

Country Link
US (3) US8969524B2 (pt)
EP (2) EP2632479B1 (pt)
JP (2) JP6122780B2 (pt)
KR (2) KR102040867B1 (pt)
CN (2) CN103298482B (pt)
AR (1) AR083586A1 (pt)
AU (2) AU2011319747C1 (pt)
BR (1) BR112013010362A2 (pt)
CA (1) CA2815239C (pt)
DK (1) DK2632479T3 (pt)
EA (1) EA034494B1 (pt)
ES (2) ES2912455T3 (pt)
HK (1) HK1215442A1 (pt)
MX (1) MX347805B (pt)
NZ (2) NZ609474A (pt)
PL (2) PL2632479T3 (pt)
PT (1) PT2632479T (pt)
SG (2) SG10201600656WA (pt)
TW (3) TW201730205A (pt)
WO (1) WO2012058480A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
DK2917232T3 (en) * 2012-11-12 2017-06-12 Apitope Int Nv FACTOR VIII DERIVATIVE PEPTIDES TO USE FOR TREATMENT OF HAEMOPHYL A
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
BR112015023793A2 (pt) * 2013-03-15 2017-07-18 Us Dept Veterans Affairs composições e métodos de terapias para indução de tolerância imune a substituição do fator vii em indivíduos com hemofilia a
US20170128544A1 (en) * 2014-06-12 2017-05-11 University Of Hawaii Uses of Humanized Cobra Venom Factor for Reducing or Preventing Immunogenicity
MX2017009181A (es) * 2015-01-26 2017-11-22 Cellectis Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
AU2017250570B2 (en) 2016-04-15 2024-07-25 Takeda Pharmaceutical Company Limited Method and apparatus for providing a pharmacokinetic drug dosing regiment
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04010061A (es) * 2002-04-18 2004-12-13 Merck Patent Gmbh Factor viii modificado.
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
DK1766412T3 (da) * 2004-05-21 2009-05-25 Inst Systems Biology Sammensætninger og fremgangsmåder til kvantificering af serumglycoproteiner
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
KR101423344B1 (ko) 2006-01-04 2014-07-30 백스터 인터내셔널 인코포레이티드 올리고펩티드-무함유 세포 배양 배지를 이용하여 단백질을 발현시키는 방법
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
US7673687B2 (en) 2007-12-05 2010-03-09 Halliburton Energy Services, Inc. Cement compositions comprising crystalline organic materials and methods of using same
DE202007017320U1 (de) 2007-12-07 2008-02-28 Dittmann, Ludwig Vorrichtung zur Raumbeduftung
GB0801513D0 (en) 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
WO2009099991A2 (en) 2008-01-31 2009-08-13 The Brigham And Women's Hospital, Inc. Treatment of cancer
AU2009313325B2 (en) 2008-11-07 2014-05-01 Takeda Pharmaceutical Company Limited Factor VIII formulations

Also Published As

Publication number Publication date
KR102040867B1 (ko) 2019-11-07
AU2016202155B2 (en) 2018-02-01
KR20130128404A (ko) 2013-11-26
AU2016202155A1 (en) 2016-04-28
EP3260132B1 (en) 2022-02-09
NZ703514A (en) 2017-02-24
NZ609474A (en) 2015-06-26
US8969524B2 (en) 2015-03-03
CA2815239A1 (en) 2012-05-03
EP2632479A1 (en) 2013-09-04
DK2632479T3 (en) 2017-08-07
JP6122780B2 (ja) 2017-04-26
CN103298482A (zh) 2013-09-11
SG189914A1 (en) 2013-06-28
JP2017095463A (ja) 2017-06-01
ES2912455T3 (es) 2022-05-26
CA2815239C (en) 2019-02-26
SG10201600656WA (en) 2016-02-26
KR20190126189A (ko) 2019-11-08
US9512198B2 (en) 2016-12-06
BR112013010362A2 (pt) 2016-08-02
US20120135019A1 (en) 2012-05-31
EP3260132A1 (en) 2017-12-27
EA201390617A1 (ru) 2013-10-30
MX2013004753A (es) 2013-09-13
JP2014505014A (ja) 2014-02-27
TW201730205A (zh) 2017-09-01
PL2632479T3 (pl) 2017-09-29
ES2639039T3 (es) 2017-10-25
AU2011319747B2 (en) 2016-01-07
TW201708251A (zh) 2017-03-01
AR083586A1 (es) 2013-03-06
WO2012058480A1 (en) 2012-05-03
EA034494B1 (ru) 2020-02-13
EP2632479B1 (en) 2017-06-14
US20170267743A1 (en) 2017-09-21
HK1215442A1 (zh) 2016-08-26
CN103298482B (zh) 2015-08-19
TW201231065A (en) 2012-08-01
CN104926947A (zh) 2015-09-23
AU2011319747A1 (en) 2013-05-02
TWI580430B (zh) 2017-05-01
PL3260132T3 (pl) 2022-08-08
KR102222864B1 (ko) 2021-03-04
AU2011319747C1 (en) 2016-07-14
US20150203567A1 (en) 2015-07-23
MX347805B (es) 2017-05-15

Similar Documents

Publication Publication Date Title
HK1215442A1 (zh) 用於免疫耐受性誘導和免疫診斷的
EP2598120A4 (en) COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE
HK1259341A1 (zh) 牛物種中增强的免疫應答
EP2661442A4 (en) MONOMERS AND MULTIMES IMMUNOGENE PEPTIDES
EP2521564A4 (en) APOE PEPTIDE DIMERS AND USES THEREOF
EP2531001A4 (en) INDUCTION COOKER
GB201012651D0 (en) Peptides
EP2593595A4 (en) NOVEL PEPTIDES AND USES THEREOF
EP2605786A4 (en) THERAPEUTIC PEPTIDES
HK1181243A1 (en) Induction cooking device
EP2552470A4 (en) PEPTIDES FOR ANGIOGENESIS PROMOTION AND USE THEREOF
EP2793921A4 (en) PEPTIDES DERIVED FROM SAPOSIN A AND USES THEREOF
HK1184774A1 (zh) 人員運送裝置
EP2834356A4 (en) RECOMBINANT BACTERIUM FOR INDUCING A CELLULAR IMMUNE RESPONSE
PL2627668T3 (pl) Peptydy i ich zastosowanie
HK1168622A1 (en) Antigen peptide and use thereof
EP2610619A4 (en) HEMOCININE-1 RECEPTOR AND HEMOCININE-1-PEPTIDE
HK1173358A1 (en) Fviii-derived peptides fviii
EP2624856A4 (en) MOESINFRAGMENTS WITH IMMUNO THROMBO CYTOPENIA
EP2627674A4 (en) EGFR BASED PEPTIDES
EP2591799A4 (en) CANCER PEPTIDE VACCINE
EP2786145A4 (en) MELITTIN PEPTIDE CONJUGATES AND THESE USES
EP2742944A4 (en) immunotolerance
EP2763659A4 (en) COMPOSITIONS AND METHODS OF INDUCING IMMUNO TOLERANCE
EP2587886A4 (en) INDUCTION COOKING DEVICE